Results 271 to 280 of about 604,743 (325)

In‐Depth Profiling Highlights the Effect of Efgartigimod on Peripheral Innate and Adaptive Immune Cells in Myasthenia Gravis

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Myasthenia gravis (MG) is an autoimmune disorder characterized by antibody‐mediated complement activation. Efgartigimod, a neonatal Fc receptor (FcRn) antagonist, is approved for treating generalized MG (gMG). However, its modulatory effects on upstream innate and adaptive immune cells remain largely unexplored.
Lei Jin   +11 more
wiley   +1 more source

SOEMPI: A Secure Open Enterprise Master Patient Index Software Toolkit for Private Record Linkage.

open access: green, 2014
Csaba D. Tóth   +4 more
openalex   +1 more source

Home - About - Disclaimer - Privacy